about
Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenograftsEvaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer XenograftsInitial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing ConsortiumEvaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft modelsPreclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium reportEvaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium
P50
Q47591626-1F98C614-CD02-42A9-A5A9-F0122C019E6FQ47786231-89B699E7-DB9B-4E0F-B188-42397F88362DQ90224971-987663FB-6C1F-4013-91DF-67E88BFD8950Q90407359-7599B22F-7365-4B10-B640-F6630AAFE502Q90618472-241D67BD-31BC-4DF9-B798-C3515C473EF6Q92104678-EDDDCDA0-494C-4172-8076-E3640154548CQ92896023-651CD1A1-3153-4ADF-8A7B-3E151F85E5A2Q93219866-C01E21C0-1E4E-413C-941B-B4DE6113ACAB
P50
description
researcher
@en
wetenschapper
@nl
name
Raushan T Kurmasheva
@en
Raushan T Kurmasheva
@nl
type
label
Raushan T Kurmasheva
@en
Raushan T Kurmasheva
@nl
prefLabel
Raushan T Kurmasheva
@en
Raushan T Kurmasheva
@nl
P31
P496
0000-0003-3212-2363